机译:Bapineuzumab在轻度至中度阿尔茨海默病患者中的长期安全性和疗效:2阶段,开放标签扩展研究
The Warren Alpert Medical School of Brown University;
Center for Alzheimer Research &
Treatment Department of Neurology Brigham and Women's Hospital;
Janssen Research &
Development Springhouse;
Janssen Research &
Development Pennington;
Alzheimer's disease; bapineuzumab; MRI; brain amyloid-related imaging abnormality; AD assessment scale; disabilityassessment for dementia; Alzheimer's disease; bapineuzumab; MRI; brain amyloid-related imaging abnormality; AD assessment scale; disabilityassessment for dementia;
机译:Bapineuzumab在轻度至中度阿尔茨海默病患者中的长期安全性和疗效:2阶段,开放标签扩展研究
机译:在两项3期扩展研究中,bapineuzumab对阿尔茨海默氏病患者的长期安全性和耐受性
机译:一项为期24周的开放标签扩展研究,用于研究重度阿尔茨海默氏病患者中13.3 mg / 24 h Rivastigmine贴剂的长期安全性,耐受性和功效
机译:认知干预对老年人和阿尔茨海默氏病患者疗效的随机,安慰剂对照研究
机译:免疫调节药物来那度胺在淋巴瘤患者中的安全性和有效性:RU051417I-R-ICE(利妥昔单抗-异环磷酰胺-卡铂-依托泊苷)与来那度胺[R2-ICE]的I / II期开放标签研究的进展初次复发/原发性难治性弥漫性大B细胞淋巴瘤(DLBCL)。
机译:在两项3期扩展研究中bapineuzumab对阿尔茨海默氏病患者的长期安全性和耐受性
机译:在两项3期扩展研究中,bapineuzumab对阿尔茨海默氏病患者的长期安全性和耐受性